Resources - Entheo

Overview

Pressman, T. (1992)

The Therapeutic Potential of Nonordinary States of Consciousness, as Explored in the Work of Stanislav Grof. Journal of Humanistic Psychology.

Nichols, David. (2016)

Psychedelics. Pharmacology Reviews.

Haijen et al. (2018)

Predicting responses to psychedelics: a prospective study. Frontiers in Pharmacology.

Johnson et al. (2021).

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology and Therapeutics.

Holez et al. (2022).

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology.

Carhart-Harris et al. (2018).

Psychedelics and the essential importance of context. Journalof Psychopharmacology.

Carhart-Harris, Robin. (2019).

How do psychedelics work? Current Opinion in Psychiatry.

Carhart-Harris et al. (2013).

Experienced drug users assess the relative harms and benefits of drugs: A Web-based survey. Journal of Psychoactive Drugs.

History

Ruck et al. (1979).

Entheogens. Journal of Psychedelic Drugs

Doblin, Rick. (1991).

Pahnke's "Good Friday Experiment”: a long-term follow-up and methodological critique. Journal of Transpersonal Psychology

Merlin, M. (2003).

Archaeological Evidence for the Tradition of Psychoactive Plant Use in the Old World. JSTOR.

Dyck, Erika. (2005).

Flashback: Psychiatric Experimentation with LSD in Historical Perspective. Canadian Journal of Psychiatry.

Carhart-harris and Goodwin. (2021).

Psychiatry and psychedelic drugs. Past, present & future. Neuropharmacology.

Lieberman, Jeffrey. (2021).

Back to the Future — The Therapeutic Potential of Psychedelic Drugs. New England Journal of Medicine.

Hall, Wayne. (2022).

Why was early therapeutic research on psychedelic drugs abandoned? Psychological Medicine.

Rucker et al. (2018)

Psychiatry and psychedelic drugs. Past, present & future. Neuropharmacology.

Safety

Johnson et al. (2008)

Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology.

Nutt et al. (2010)

Drug harms in the UK: a multicriteria decision analysis. Lancet.

Van Amsterdam et al. (2010)

Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. European Addiction Research.

Aday et al. (2021)

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacological Translational Science.

Phelps, Janis. (2017)

Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology.

Kopra et al. (2022)

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Journal of Psychopharmacology.

Gable, Robert. (2004)

Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction.

Stone et al. (2007)

Who Is Becoming Hallucinogen Dependent Soon After Hallucinogen Use Starts? Drug and Alcohol Dependence.

Brunt et al. (2012)

Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology.

Van Amsterdam et al. (2015)

European ratings of drug harms. Psychopharmacology.

Van Amsterdam et al. (2020)

Fatal and non-fatal health incidents related to recreational ecstasy use. Psychopharmacology.

Kopra et al. (2022)

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). Journal of Psychopharmacology.

Schlag et al. (2022)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Psychopharmacology.

Johnston et al. (2023)

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. American Journal of Geriatric Psychiatry.

Set and Setting

Hartogsohn, Ido. (2016)

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology.

Hartogsohn, Ido. (2017)

Constructing drug effects: A history of set and setting. Drug, Science, Policy and Law.

Barrett et al. (2018)

Psychedelics and music: neuroscience and therapeutic implications. International Review of Psychiatry.

McCartney et al. (2022

Predictors of Psychedelic Experience: A Thematic Analysis. Journal of Psychoactive Drugs.

The Difficult Journey

Strassman, R. J. (1984)

Adverse reactions to psychedelic drugs. A review of the literature. Journal of Nervous and Mental Disease.

Barrett et al. (2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology.

Carbonaro, et al. (2016)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology

Barrett et al. (2017)

Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences.

Dyck and Elcock. (2020)

Reframing Bummer Trips: Scientific and Cultural Explanations to Adverse Reactions to Psychedelic Drug Use. The Alcohol and Drugs Society.

Gashi et al. (2021)

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy.

Schlag et al. (2022)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacolog

Rare and serious side-effects

Halpern and Hope Jr. (2003)

Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence.

Boyer and Shannon. (2005).

The Serotonin Syndrome. NEJM.

Rosenson et al. (2007)

Patterns of ecstasy-associated hyponatremia in California. Annals of Emergency Medicine.

Van Amsterdam et al. (2011)

Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology.

Halpern et al. (2018)

A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Current Topics in Behavioral Neuroscience.

Murrie et al. (2020)

Transition of Substance-Induced, Brief, and Atypical Psychosis to Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia bulletin.

Kuc et al. (2021)

Psychedelic experience dose-dependently modulated by cannabis: Results of a prospective online survey. Psychopharmacology.

Malcom and Thomas. (2022)

Serotonin toxicity of serotonergic psychedelics. Journal of Psychopharmacology

Buckley et al. (2014)

Serotonin Syndrome. BMJ.

Barber et al. (2022)

A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. American Journal of Psychiatry.

Psychedelics and Mental Health

Vollenweider et al. (2010)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience.

Garcia-Romeu and Richards. (2018)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review Psychiatry.

Nutt et al. (2020)

Psychedelic Psychiatry's Brave New World. Cell.

Reiff et al. (2020)

Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry.

Davis et al. (2020)

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Contextual Behavioral Science.

Davis et al. (2021)

Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. Chronic Stress.

Gregoris et al. (2021)

d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. Progressive Brain Research.

Zeifman et al. (2021)

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. ACS Pharmacology and Translational Science.

Kocarova et al. (2021)

Does psychedelic therapy have a transdiagnostic action and prophylactic potential? Frontiers in Psychiatry.

Jones and Nock. (2022)

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. Journal of Psychopharmacology.

Jones and Nock. (2022)

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Journal of Psychopharmacology

Krediet et al. (2020)

Reviewing the Potential of Psychedelics for the Treatment of PTSD. Neuropsychopharmacology.

Psychedelics and Pain:

Bonnelle et al. (2022)

Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. British Journal of Pain.

Christie et al. (2022)

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Frontiers in Psychiatry.

Schindler et al. (2022)

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache.

Psychedelics and Addictions:

Yanagita, T. (1986)

Intravenous self-administration of (-)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys. Drug and Alcohol Dependence.

Fantegrossi et al. (2004)

Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behavioral pharmacology.

Canal and Murnane. (2016)

The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology.

Johnson et al. (2017)

Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse.

Bogenschutz and Johnson. (2017)

Classic hallucinogens in the treatment of addictions. Progress in neuro-psychopharmacology.

Ross et al. (2016)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology.

Psilocybin

Bogenschutz et al. (2015)

Psilocybin-assisted treatment for alcohol dependence: a proofof-concept study. Journal of Psychopharmacology.

Griffiths et al. (2016)

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized doubleblind trial. Journal of Psychopharmacology

Carhart-Harris and Goodwin. (2017)

The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology.

Johnson et al. (2017)

Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse.

Watts et al. (2017)

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology.

Carhart-Harris et al. (2018)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology

Davis et al. (2020)

Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry.

Carhart-Harris et al. (2021)

Trial of Psilocybin versus Escitalopram for Depression. NEJM.

Becker et al. (2021)

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology and therapeutics.

Lowe et al. (2021)

The Therapeutic Potential of Psilocybin. Molecules.

Daws et al. (2022)

Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine.

Moreno et al. (2006)

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Clinical Psychiatry.

Ross et al. (2016)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology.

Goodwin et al. (2022)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. NEJM.

LSD

Blewett and Chwelos. (1959)

Handbook for the therapeutic use of lysergic acid diethylamide-25. Individual and Group Procedures.

Grof et al. (1970)

LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry.

Dishotsky, NI. (1971)

LSD and Genetic Damage. Science

Cohen, MM. (1977)

Genetic toxicology of LSD-25. Mutat Research.

Passie et al. (2008)

The Pharmacology of Lysergic Acid Diethylamide: A Review. CNS Neuroscience and Therapeutics.

Hintzen and Passie. (2010)

The Pharmacology of LSD: A Critical Review. Oxford: Beckley Foundation Press & Oxford University Press.

Gasser et al. (2014)

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. Journal of Nervous and Mental Disease.

Carhart-Harris et al. (2016)

Neural correlates of the LSD experience revealed by multimodal neuroimaging. PNAS.

Carhart-Harris et al. (2016)

The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Medicine.

Speth et al. (2016)

Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology.

Fuentes et al. (2020)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.

Kanen et al. (2022)

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. Psychological Medicine.

Holze et al. (2022)

Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biological Psychiatry.

MDMA

Hysek et al. (2012)

Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One.

Hysek et al. (2014)

The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans, Clinical Pharmacology and Therapeutics.

Wardle et al. (2014)

‘Ecstasy’ as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Social Cognitive and Affective Neuroscience.

Baggott et al. (2016)

Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. Journal of Psychopharmacology.

Bershad et al. (2016)

The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? Journal of Psychopharmacology.

Vizeli et al. (2018)

Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. Plos One.

Feduccia et al. (2019)

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMAAssisted Psychotherapy Compared to Paroxetine and Sertraline. Frontiers in Psychiatry.

Mitchell et al. (2021)

MDMA-assisted therapy for severe PTSD: a randomized, doubleblind, placebo-controlled phase 3 study. Nature Medicine.

Brewerton et al. (2022)

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. Journal of Psychiatric Research.

Fedducia et al. (2018)

MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Neuropharmacology and biological psychiatry.

Sottile and Vida. (2022)

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. Frontiers in Psychiatry.

Barone et al. (2022)

Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness. Frontiers in Psychiatry.

Microdosing

Web et al. (2019)

Narrative identity, rationality, and microdosing classic psychedelics. International Journal of Drug Policy.

Andersen et al. (2020)

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology.

Kaertner et al. (2021)

Positive expectations predict improved mental‐ health outcomes linked to psychedelic microdosing. Scientific Reports.

Rootman et al. (2021)

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Report

Rosenbaum et al. (2020)

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. Journal of Psychopharmacology.

Ona et al. (2020)

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. Neuroscience and Behavioral Reviews.

Szigeti et al. (2021)

Self-blinding citizen science to explore psychedelic microdosing. Elife.

Phenomenology

Pahnke, Walter. (1966)

Drugs and Mysticism. The International Journal of Parapsychology.

Pahnke, Walter. (1963)

The Psychedelic Mystical Experience in the Human Encounter with Death.

Pahnke and Richards. (1966)

Implications of LSD and experimental mysticism. Journal of Religion and Health,

Griffths et al. (2006)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology.

Studerus et al. (2011)

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology.

Griffths et al. (2017)

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology.

Milliere, Raphael. (2017)

Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution. Frontiers in Human Neuroscience.

Roseman et al. (2018)

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology.

Preller and Vollenweider. (2018)

Phenomenology, Structure, and Dynamic of Psychedelic States. Current topics in behavioural neuroscience.

Barrett and Griffiths. (2018)

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Current Topics in Behavioral Neuroscience.

Griffiths et al. (2019)

Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. Plos One.

Seth et al. (2022)

Theories of consciousness. Nature Reviews Neuroscience.

Nour et al. (2016)

Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience.

Smith and Sisti. (2020)

Ethics and ego dissolution: the case of psilocybin. Journal of Medical Ethics.

Integration

Prellar et al. (2017)

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Current Biology

Gashi et al. (2021)

Making ‘bad trips’ good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy 87: 102997.

Gorman, et al. (2021)

Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Frontiers in Psychology.

McGovern et al. (2022)

Do psychedelics change beliefs? Psychopharmacology.

Teixeria et al. (2022)

Psychedelics and Health Behaviour Change. Journal of Psychopharmacology.

Bathje et al. (2022)

Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology.

Nayak et al. (2022)

Belief changes and psychedelics. Journal of Psychopharmacology.

Neuroscience

Lennon et al. (1984)

Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences.

Carhart-Harris et al. (2012)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS.

Carhart-Harris et al. (2014)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Neuroscience

Carhart-Harris and Nutt. (2017)

Serotonin and brain function: a tale of two receptors. Journal of Psychopharmacology.

Ly et al. (2018)

Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports.

Carhart-Harris and Friston. (2019)

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews.

De Gregario et al. (2021)

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. Journal of Neuroscience.

Dos Santos and Hallak. (2020)

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neuroscience and Biobehaviroal Reviews.

Barrett et al. (2020)

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage.

Vollenweider, Franz. (2022)

Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience.

Girn et al. (2022)

Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. Neuroimage.

Stoliker et al. (2022)

Reduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics. Frontiers in Neuroscience.

McGowan et al. (2022)

This is your Bayesian brain on drugs: Toward a predictive processing framework for psychedelic neuroscience and phenomenology.

Gattuso et al. (2022)

Default Mode Network Modulation by Psychedelics: A Systematic Review. Int Journal of Neuropsychopharmacology.

Medications

Strassman et al. (1992)

Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology.

Bonson et al. (1996)

Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans. Neuropsychopharmacology.

Bonson and Murphy. (1996)

Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behaviour Brain Research.

Fiorella et al. (1996)

Potentiation of LSD-induced stimulus control by fluoxetine in the rat. Life Science.

Vollenweider et al. (1998)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport.

Sun-Edelstein et al. (2008)

Drug-induced serotonin syndrome: a review. Expert Opinion Drug Safety.

Pilgrim et al. (2012)

Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int.

Orlova et al. (2018)

Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA.

Malcolm and Thomas. (2021)

Serotonin toxicity of serotonergic psychedelics. Psychopharmacology.

Ruhe et al. (2019)

Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry.

Sarparast et al. (2022)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology.

Psychedelics and Antidepressants

what do we know and what could be the risks?

Bodkin and Dunlop. (2022)

Moving on with Monoamine Oxidase Inhibitors.

SSRI Tapering

Warner et al. (2006)

Antidepressant discontinuation syndrome. American Family Physician.

Schatzberg et al. (2006)

Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. Journal of Clinical Psychiatry.

Fava et al. (2015)

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.

Sorenson et al. (2022)

Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology.

Meditation

Brewer et al. (2011)

Meditation experience is associated with differences in default mode network activity and connectivity. Proc Natl Acad Sci.

Milliere et al. (2018)

Psychedelics, Meditation, and Self-Consciousness. Frontiers in Psychology.

Websites

Canadian Psychedelic Association

Click to check the website

MAPS Canada

Click to check the website

Erowid

Click to check the website

Zendo Project

Click to check the website

Spirit Pharmacist

Click to check the website

Trip Safe

Click to check the website

Tripsitter

Click to check the website

Alcohol and Drug Facts

Click to check the website

Books For Journeyers:

Consciousness Medicine

Indigenous Wisdom, Entheogens, and Expanded States of Consciousness for Healing and Growth. Francoise Bourzat

The Psychedelic Explorer's Guide

Safe, Therapeutic, and Sacred Journeys. James Fadiman Hofmann and Ott. (1980). LSD, my problem child (Vol. 5). New York: McGraw-Hill.

Lee and Shlain. (1992)

Acid dreams: The complete social history of LSD: The CIA, the sixties, and beyond

Holland, Julie. (2001)

Ecstasy : The Complete Guide : A Comprehensive Look at the Risks and Benefits of MDMA

Stanislav Grof and Christina Grof

Holotropic Breathwork

Books For Sitters:

Manual for Psychedelic Guides.

Mark Haden

The Manual of Psychedelic Support.

A Practical Guide to Establishing and Facilitating CareServices at Music Festivals and Other Events. MAPS

Phelps, Janis. (2017).

Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology

MAPS Podcast

Dr. Robin Carhart Harris

Brain imaging

Dr. Robin Carhart Harris

The Future Psychedelic Science

Dr. Ben Sessa

MDMA therapy

Dr. Matthew Bagoott

Beyond fear, MDMA, and Emotion

The Tim Ferriss Show

Michael Pollan

Exploring The New Science of Psychedelics

Francois Bourzat

Consciousness Medicine

Sam Harris

Psychedelics, How to Cope During a Pandemic, Taming Anxiety, and More

The Psychedelic News Hour

New Breakthroughs, Compound Comparisons and Warnings (Psilocybin/LSD/Ayahuasca/N,N-DMT/5-MeO-DMT), Treatment of Trauma, Scalable vs. Unscalable Approaches, Making Sense of “Bad” Trips, and Much More

Peter Attia - The Drive

Rick Doblin

MDMA - the creation, scheduling, toxicity, therapeutic use, and changing public opinion of what is possibly the single most important synthetic molecule ever created by our species

David Nutt

Psychedelics and Recreational Drugs

Sam Harris

The Transformative Power of Mindfulness

Huberman Lab

Dr. Nolan Williams

Psychedelics and Neurostimulation for Brain Rewiring

Dr. Matthew Johnson

Psychedelics for Treating Mental Disorders

Andrew Huberman

The Science of MDMA & Its Therapeutic Uses: Benefits & Risks

Dr. Robin Carhart-Harris

The Science of Psychedelics for Mental Health

Andrew Huberman

How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks

Sam Harris - Making Sense

Roland Griffiths

Psychedelics and Mortality

Roland Griffiths

Psychedelic Science

James Fadiman

Psychedelics and the Self

Sam Harris

Phenomenology of a Mushroom Trip

Numinus presents: Psychedelic Therapy Frontiers

How to prepare for a psychedelic journey

The art and science of psychedelic trip sitting

How to set intentions for psychedelic therapy…and life

TED:

Anil Seth

Mystery’s of Consciousness

Rick Doblin

The Future of Psychedelic-assisted Psychotherapy

Roland Griffths

The Science of Psilocybin and It’s Use to Relieve Suffering

Research and Resources

Overview

Pressman, T. (1992)

Nichols, David. (2016)

Haijen et al. (2018)

Johnson et al. (2021).

Holez et al. (2022).

Carhart-Harris et al. (2018).

Carhart-Harris, Robin. (2019).

Carhart-Harris et al. (2013).

History

Ruck et al. (1979).

Doblin, Rick. (1991).

Merlin, M. (2003).

Dyck, Erika. (2005).

Carhart-harris and Goodwin. (2021).

Lieberman, Jeffrey. (2021).

Hall, Wayne. (2022).

Rucker et al. (2018)

Safety

Johnson et al. (2008)

Nutt et al. (2010)

Van Amsterdam et al. (2010)

Aday et al. (2021)

Phelps, Janis. (2017)

Kopra et al. (2022)

Gable, Robert. (2004)

Stone et al. (2007)

Brunt et al. (2012)

Van Amsterdam et al. (2015)

Van Amsterdam et al. (2020)

Kopra et al. (2022)

Schlag et al. (2022)

Johnston et al. (2023)

Set and Setting

Hartogsohn, Ido. (2016)

Hartogsohn, Ido. (2017)

Barrett et al. (2018)

McCartney et al. (2022

The Difficult Journey

Strassman, R. J. (1984)

Barrett et al. (2016)

Carbonaro, et al. (2016)

Barrett et al. (2017)

Dyck and Elcock. (2020)

Gashi et al. (2021)

Schlag et al. (2022)

Rare and serious side-effects

Halpern and Hope Jr. (2003)

Boyer and Shannon. (2005).

Rosenson et al. (2007)

Van Amsterdam et al. (2011)

Halpern et al. (2018)

Murrie et al. (2020)

Kuc et al. (2021)

Malcom and Thomas. (2022)

Buckley et al. (2014)

Barber et al. (2022)

Psychedelics and Mental Health

Vollenweider et al. (2010)

Garcia-Romeu and Richards. (2018)

Nutt et al. (2020)

Reiff et al. (2020)

Davis et al. (2020)

Davis et al. (2021)

Gregoris et al. (2021)

Zeifman et al. (2021)

Kocarova et al. (2021)

Jones and Nock. (2022)

Jones and Nock. (2022)

Krediet et al. (2020)

Psychedelics and Pain:

Bonnelle et al. (2022)

Christie et al. (2022)

Schindler et al. (2022)

Psychedelics and Addictions:

Yanagita, T. (1986)

Fantegrossi et al. (2004)

Canal and Murnane. (2016)

Johnson et al. (2017)